Post-transplantation malignancies: here today, gone tomorrow?

Area of Science:

• Immunology
• Oncology
• Transplantation Medicine

Background:

• Increased cancer incidence is a known risk in transplant recipients due to long-term immunosuppression.
• Post-transplant malignancy accounts for 10-30% of deaths, with rising trends.
• Identifying high-risk patient groups and understanding susceptibility are crucial.

Purpose of the Study:

• To summarize cancer incidence and types in transplant recipients.
• To examine risk factors and reasons for cancer susceptibility.
• To discuss strategies for reducing post-transplant malignancies and evaluate immunosuppressive drug efficacy.

Main Methods:

• Review of registry data on cancer incidence and types.
• Analysis of factors contributing to cancer risk in immunosuppressed patients.
• Discussion of immunosuppressive drug effects, focusing on mammalian target of rapamycin (mTOR) inhibitors.

Main Results:

• Certain transplant recipients face higher malignancy risks.
• Mammalian target of rapamycin (mTOR) inhibitors exhibit both immunosuppressive and anti-neoplastic properties.
• Clinical data on mTOR inhibitor use in managing post-transplant cancers are presented.

Conclusions:

• High rates of post-transplant malignancy necessitate improved management strategies.
• Understanding the complex mechanisms of mTOR inhibitors is key to optimizing cancer prevention and treatment.
• Future perspectives aim to normalize cancer incidence in transplant recipients.